ARRY-162 is a potent and selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinase), which plays a key role in the RAS/RAF/MEK/ERK signaling pathway. This pathway is frequently dysregulated in various cancers, particularly those with mutations in BRAF or RAS genes. ARRY-162 has been investigated for its potential in oncology research, especially in the development of targeted cancer therapies. It is used primarily in preclinical studies to evaluate the effects of MEK inhibition on tumor cell proliferation, survival, and signaling pathway modulation. Its application supports the discovery and validation of therapeutic strategies for melanoma, non-small cell lung cancer, and other malignancies driven by aberrant MAPK signaling. Due to its research-grade use, ARRY-162 serves as a tool compound for understanding resistance mechanisms and combination treatment approaches with other kinase inhibitors.